The key catalyst is FDA acceptance of the NDA within ~30 days and the subsequent PDUFA date assignment. If accepted, the stock will trade on a 6-month approval timeline with no clinical risk. Monitor for any FDA request for inspection of the new vendor or the original vendor's reinspection outcome, which could accelerate or delay the timeline.
Price Chart
Executive Summary
Unicycive Therapeutics resubmitted its NDA for oxylanthanum carbonate (OLC) to the FDA on September 29, 2026, using a new third-party manufacturing vendor with a clean FDA inspection record, after receiving a Complete Response Letter in June 2026 due to unresolved manufacturing issues at the original vendor. The company also appointed Meredith S. Manning, a seasoned biopharma commercial executive, as an independent director effective October 1, 2026. The NDA resubmission addresses the sole remaining regulatory hurdle (CMC/manufacturing) and, if accepted, sets a new PDUFA date approximately 6 months out, with $61.4M in cash providing runway into 2H 2027.
Key Facts
- NDA resubmission for oxylanthanum carbonate (OLC) submitted September 29, 2026
- New third-party manufacturing vendor has 'No Action Indicated' FDA inspection status from March 2024
- 12 months of OLC drug product stability data from new vendor included in resubmission
- Company anticipates FDA acceptance within 30 days and new PDUFA date ~6 months from resubmission
- Prior CRLs in June 2025 and June 2026 cited only third-party manufacturing deficiencies; no clinical safety/efficacy concerns raised
- Unaudited cash, cash equivalents and marketable securities totaled $61.4M as of June 30, 2026, providing runway into 2H 2027
- Appointed Meredith S. Manning as independent director effective October 1, 2026; she has 25+ years biopharma commercial experience including multiple FDA approvals and launches
Financial Impact
Cash position of $61.4M provides runway into 2H 2027; NDA resubmission addresses sole remaining regulatory hurdle for OLC, which targets a U.S. market of over 450,000 ESRD patients requiring phosphate binders annually
Risk Factors
- FDA may not accept the NDA within 30 days or may require additional information
- Original third-party manufacturing vendor's reinspection could still delay or prevent approval if unfavorable
- Commercial launch execution risk for a clinical-stage company with no prior product revenue
- Potential need for additional capital if cash runway is insufficient to reach approval and launch
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-104314 |
| Document: ea030696701ex99-1.htm | 0001213900-26-104314 |
| Document: 0001213900-26-104314-index-headers.html | 0001213900-26-104314 |
| Document: 0001213900-26-104314-index.html | 0001213900-26-104314 |
| Document: 0001213900-26-104314.txt | 0001213900-26-104314 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.62 (−14.22%) |
Sep 29, 2026 28d ago | 8-K | $4.55 | awaiting T+60 | — | $3.62 (−20.44%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.62 (−32.84%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.62 (−36.82%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.62 (−54.00%) |
Jun 16, 2026 19w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.62 (+49.51%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.62 (+45.65%) |
May 12, 2026 24w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.62 (−55.69%) |
May 12, 2026 24w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.62 (+55.69%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.62 (−45.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers